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ABSTRACT  28 
Autogenous staphylococcal bacterins are commonly mentioned as treatment for canine 29 
recurrent pyoderma but little evidence is known about their efficacy. This retrospective 30 
study describes use and assesses efficacy of an autogenous Staphylococcus 31 
(pseud)intermedius bacterin in dogs with pyoderma. Frequency and duration of systemic 32 
antimicrobial therapy were compared 12 months before and after starting bacterin 33 
(Wilcoxon-signed-rank test) with data extracted from general practice medical histories.  34 
Bacterin orders had been received by the laboratory for 231 dogs over a 12.5-year period. 35 
Complete medical records could be obtained for 22 dogs. All had received at least one 36 
course (median 5, range 1-10) of systemic antimicrobials before starting bacterin. After 37 
starting bacterin, five dogs (22.7%) did not receive any antimicrobials systemically; 17 38 
(77.3%) received fewer courses and days compared to the preceding 12 months (P=0.007 39 
for both courses and days). No bacterin-associated adverse effects had been recorded.  40 
Although primary causes for pyoderma and the effect of topical therapy were not controlled 41 
in this study, the data provide additional evidence of a beneficial effect of autogenous S. 42 
pseudintermedius bacterin in the management of canine recurrent pyoderma. Autogenous 43 
bacterin therapy should be studied further as an aid to treatment in the context of good 44 
antimicrobial stewardship.  45 
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INTRODUCTION 46 
With antimicrobial resistance as a major threat to human and animal health, veterinary 47 
prescribing of antimicrobial drugs is under scrutiny, for both livestock and for companion 48 
animals. Canine pyoderma remains one of the most common diseases diagnosed in small 49 
animal practice,1 2 frequently leads to antimicrobial prescribing3 and is often recurrent due 50 
to undiagnosed or uncontrolled underlying primary triggers.4-7  51 
Repeated systemic antibacterial treatment is discouraged in order to reduce resistance 52 
selection pressure on skin microflora and skin pathogens.8 However, other management 53 
options for recurrent pyoderma are scarce, with topical antibacterial therapy as an 54 
attractive, but not always practical, alternative.9-11 Immunomodulation or immunisation 55 
through staphylococcal vaccines have been explored for many decades, mainly for 56 
application in bovine mastitis and in human furunculosis and rhinitis.12-15 In human 57 
medicine, several vaccine candidates, targeting different antigens, have progressed 58 
through to clinical trials but efficacy against invasive S. aureus infections in clinical phase 59 
III stages have so far been disappointing.16 17 60 
Bacterins, defined as suspensions typically of lysed or attenuated bacteria used as 61 
vaccines to increase immunity to particular pathogens or a disease, have been used 62 
sporadically in dogs for staphylococcal blepharitis18 and for recurrent staphylococcal 63 
pyoderma.19-24 Clinical benefits have been reported but associated immunological changes 64 
remain rarely studied25 and poorly understood.  65 
Two early bacterin studies published in the 1980s already indicated a beneficial effect as 66 
adjunctive therapy in the management of superficial and deep canine pyoderma. One was 67 
a Propionibacterium acnes (now referred to as Cutibacterium acnes)26 suspension,19 the 68 
other an autogenous ‘S. aureus’ lysate (possibly S. pseudintermedius in current 69 
taxonomy).20 However, the intravenous injection route for the P. acnes product and the 70 
high incidence of local and systemic adverse reactions with the S. aureus bacterin limited 71 
practical clinical utility.    72 
Later, two controlled studies assessed the efficacy of bacterins specifically in dogs with superficial 73 
pyoderma. Staphage Lysate (SPL, Delmont Laboratories, Swarthmore, PA, U.S.A.), a phage 74 
lysate of well-characterised S. aureus cultures, commercially available in the U.S.A. and selected 75 
other countries, was tested in 21 dogs with superficial pyoderma against placebo in a double-76 
blinded design with twice weekly subcutaneous injections over 18 weeks and once or twice 77 
weekly washing with a benzoyl peroxide shampoo for both groups.21 A beneficial effect was seen 78 
in 77% of dogs in the treatment group with regard to milder or less frequent recurrence of 79 
pyoderma or reduced need of antimicrobials compared to 37% improvement in the placebo group. 80 
Efficacy was also reported for an autogenous S. (pseud)intermedius bacterin formulated through 81 
phenol and formalin processing of the patient’s own pathogenic staphylococcal isolate.22 After a 82 
ten-week, single-blinded treatment period, lesion scores in the five control group dogs were 83 
significantly higher than those in the five dogs receiving subcutaneous bacterin injections. In both 84 
studies, systemic antibiotics were given initially in parallel to bacterin therapy for six and four 85 
weeks respectively, reflecting the concept of bacterins as an aid to prevent recurrences rather 86 
than a treatment for active infection. Lastly, two uncontrolled studies reported beneficial effects on 87 
clinical signs in dogs with recurrent pyoderma. The SPL reduced pruritus scores in 13 atopic 88 
dogs23 and another S. aureus lysate, originally developed for use in bovine mastitis (Lysigin, 89 
Boehringer Ingelheim Vetmedica, Inc. St. Joseph, MO, U.S.A.) reportedly improved pyoderma 90 
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lesions in all ten dogs with superficial pyoderma and in nine of eleven dogs with deep pyoderma 91 
over a four-month period of subcutaneous injections.24 92 
Our retrospective study aimed to describe how the autogenous S. (pseud)intermedius bacterin 93 
previously investigated by Curtis et al.22 is used in veterinary practice and to assess whether it 94 
could reduce the need for systemic antimicrobial therapy in dogs with recurrent pyoderma. 95 
 96 
MATERIALS AND METHODS 97 
Ethics 98 
The study had been approved by the Royal Veterinary College (RVC) Ethics and Welfare 99 
Committee (URN 2014 1294).  100 
Bacterin orders and treatment recommendations 101 
Information on autogenous Staphylococcus (pseud)intermedius bacterins ordered for dogs 102 
from the RVC microbiology laboratory between January 2002 and June 2014 was 103 
reviewed. Bacterins had been formulated as previously described (production discontinued 104 
since 2018) from clinical isolates of S. pseudintermedius (S. intermedius prior to 2009) 105 
through processing with phenol and formalin.22 Bacteria had been isolated from clinical 106 
samples submitted by veterinary surgeons (first opinion veterinarians and referral 107 
veterinary dermatologists) for bacterial culture, antimicrobial susceptibility testing and 108 
bacterin production, or isolates had been submitted for bacterin formulation via another 109 
diagnostic laboratory on behalf of the submitting veterinary surgeon. 110 
Bacterins were posted to submitting practices with instructions for subcutaneous 111 
administration (Table 1). Antimicrobial treatment before and during the start of bacterin 112 
therapy was at the veterinary surgeon’s discretion but discontinuation approximately ten 113 
days into bacterin treatment was recommended. Numbers of first orders, of subsequent 114 
repeat orders and intervals between first orders and first and last repeat orders were 115 
recorded. Based on volume (40ml per vial) and recommended injection protocol, one vial 116 
was assumed to provide 81 days of induction course treatment and between 91 and 192 117 
days of maintenance treatment at either weekly or fortnightly dosing. Orders submitted 118 
after more than 192 days were included as new orders. 119 
Antimicrobial use and clinical characteristics 120 
Antimicrobial use before and during bacterin therapy, including treatment during the start 121 
of bacterin injections, was investigated by retrospective analysis of the dogs’ medical 122 
records. Practices in the U.K. that had ordered bacterin for a dog with a methicillin-123 
susceptible S. (pseud)intermedius and for which addresses could still be obtained from the 124 
RVC laboratory database were asked in writing to send patient medical histories covering 125 
12 months before and 12 months after starting bacterin therapy. Practices were asked to 126 
submit medical records coded with the study number provided on the covering letter and 127 
with all owner identifiable data deleted. Medical histories were not requested if bacterins 128 
had been ordered through another microbiology laboratory on behalf of the attending 129 
veterinary surgeon. One follow-up phone call was made two to four weeks after the initial 130 
request if histories had not been received.  131 
Medical histories were analysed for signalment (recorded as close as possible to the start 132 
of bacterin therapy), diagnosis of skin disease (as recorded by submitting practices or as 133 
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predicted from descriptions of lesion type), timing and duration of bacterin injections and 134 
for systemic (days of drug prescribed for bacterial infections) and topical (prescribed or 135 
not) antibacterial therapy. Pyoderma was classified based on clinical signs into superficial 136 
(papules, pustules, epidermal collarettes) or deep (furuncles, sinuses, haemorrhagic 137 
crusts). Records of adverse reactions in a timely association with bacterin injections were 138 
noted.  139 
Statistical Analysis 140 
Data were described and analysed using SPSS Version 22.0 (IBM Corp. Released 2013. 141 
IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY). Distribution of data was 142 
tested for normality using the Shapiro-Wilk test. Differences between numbers of days and 143 
numbers of courses of antimicrobial drugs prescribed for systemic use were compared 144 
before and during bacterin therapy for each dog by Wilcoxon signed rank test. P<0.05 was 145 
considered statistically significant. 146 
 147 
RESULTS 148 
Bacterin orders 149 
Totals of 231 new S. (pseud)intermedius bacterin requests (mean 18 per year, SD 6.7) 150 
and of 480 repeat orders (mean 38 per year, SD 12.2) were received by the RVC 151 
laboratory during the twelve-and-a-half-year study period. Of the 231 dogs for which 152 
bacterin had been ordered, 137 (59.3%) continued with at least one repeat order. The 153 
number of repeat orders per individual dog ranged from 1 to 16 (median 3) with repeats 154 
ordered only once for 47 (20.3%) dogs, twice for 19 (8.2%) dogs and more than twice for 155 
71 (30.7%) dogs. Orders for first repeat bacterin vials were received within 13 weeks of the 156 
first order for 68 (50%) dogs, in compliance with the expected ordering interval according 157 
to the dosing protocol. Of 305 ordering intervals available for consecutive repeat orders, 158 
75.1% were within the appropriate predicted treatment duration. 159 
Clinical characteristics of bacterin-treated dogs 160 
Medical histories were requested for 144 of the 231 dogs from 47 different primary 161 
practices. Medical records were not requested for the remainder as dogs either lived 162 
outside the U.K. (n=12, all in Germany), bacterin had been ordered through another U.K. 163 
diagnostic laboratory (n=39), addresses for submitting practices were no longer valid 164 
(n=31) or medical records for the relevant period could not be accessed conveniently after 165 
practices had changed from paper to computer records (n=5).  166 
Records were returned for 45 of the 144 dogs (31.3% response rate) with information 167 
covering the required 24-month period for 22 dogs (signalment in Table 2). In addition to 168 
their pyoderma management, eleven dogs (50%) received ectoparasite prophylaxis 169 
prescribed by their veterinary surgeons during their study periods. Allergic skin disease 170 
was recorded as diagnosed or suspected based on clinical signs in 17 (77.3%) dogs. 171 
Eleven of those (64.7%) received concurrent treatment with a systemic glucocorticoid (10 172 
dogs) or ciclosporin (1 dog) for management of underlying allergic disease; there was no 173 
difference between the number of dogs responding or not responding to bacterin 174 
(antimicrobial courses reduced or not) between allergic patients receiving systemic anti-175 
inflammatory treatment and those that did not (P=0.65 and P=0.98, 2-tailed Fishers exact 176 
for antimicrobial courses and days respectively). Other chronic diseases mentioned were 177 
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hypothyroidism in two dogs, a keratinisation disorder in one and heart disease in another 178 
three dogs, all managed with systemic or topical medication in parallel to their pyoderma.  179 
No adverse effects (at injection sites, or to general health) had been recorded in a timely 180 
relation to bacterin therapy in any of the dogs.  181 
Antimicrobial use before and during bacterin therapy 182 
In the 12 months before starting bacterin therapy, all 22 dogs had received at least one 183 
course or a minimum of 14 days of systemic antimicrobials (Table 2). In the 12 months 184 
after starting bacterin therapy, five dogs (23%), four with superficial and one with deep 185 
pyoderma, had not received any systemically used antimicrobials. Fewer courses and 186 
fewer days of systemic antimicrobial therapy had been prescribed during the 12 months 187 
following the start of bacterin therapy compared to the 12 months preceding bacterin 188 
(P=0.007 for both courses and days comparing all 22 dogs). Ranges and medians are 189 
shown in Table 2. When only comparing the 19 dogs for which at least one repeat bacterin 190 
order had been received and which had therefore likely received at least 172 days of 191 
bacterin therapy, antimicrobial prescribing before and after bacterin start was also reduced 192 
for courses and days (both P=0.02).   193 
Six different classes of systemic antimicrobial drugs had been prescribed for the 22 dogs. 194 
All but one had received a -lactam antibiotic on at least one occasion during their 24-195 
month study period (cephalexin prescribed for 20 dogs, amoxicillin-clavulanic acid for 13 196 
dogs, cefovecin for 4 dogs on at least one occasion), clindamycin had been used in 5 197 
dogs, a fluoroquinolone in 7, and 1 dog had been treated with trimethoprim-potentiated 198 
sulphonamide. Topical antimicrobial therapy had been dispensed in addition to systemic 199 
treatment in 15/22 (68%) dogs during the 24-month periods but prescriptions were too 200 
infrequent to allow useful allocation into periods before and after starting bacterins. 201 
Prescription-only, chlorhexidine-based shampoos (Malaseb, Dechra Veterinary Products, 202 
Shrewsbury, U.K.; Microbex, Virbac Limited, Woolpit, U.K.) indicated for the management 203 
of microbial skin infections had been used for 8/22 (36%) dogs, another six dogs had 204 
received other antibacterial wash preparations (chlorhexidine, hypochloric acid or 205 
chloroxylenol-based products) and one dog had received fusidic acid cream as the only 206 
topical product. Of the five dogs that had been managed without systemic antimicrobials 207 
after starting bacterin, three continued with antimicrobial shampoo therapy. Antimicrobial 208 
eardrops had been prescribed for 10/22 dogs at least once during the 24 months periods. 209 
DISCUSSION 210 
Within the limitations of a retrospective study using general practice medical records, our 211 
results suggest that autogenous S. (pseud)intermedius bacterin can help to reduce the 212 
need for systemic antimicrobial therapy in the management of canine recurrent pyoderma. 213 
For the first time in canine pyoderma, this study analysed the need for antimicrobial 214 
medication during bacterin therapy over a long period, rather than clinical signs during 215 
shorter trials as in previous studies. The reduced need for antimicrobial therapy is in line 216 
with findings from a recent study in pigs where an autogenous S. hyicus vaccine used in 217 
sows reduced the metaphylactic use of antimicrobials in their piglets during outbreaks of 218 
exudative epidermitis but where management and other concurrent factors were well 219 
controlled.27 Reducing the need for systemic antimicrobials in dogs is of particular 220 
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relevance at a time when calls to reduce antimicrobial use in companion animals, and in 221 
some countries restrictions on prescribing, are increasing.28-30 222 
Acceptance of the bacterin therapy amongst owners and veterinary surgeons and safety in 223 
the dogs appeared good based on repeat orders received for almost 60% of dogs after the 224 
initial 80-day course and the lack of any mention of adverse reactions in the medical 225 
records of the 22 dogs. 226 
Important confounding factors in this study were the lack of standardisation or control of 227 
diagnostic criteria and of primary causes for pyoderma. Diagnostic detail such as the level 228 
of depth for pyoderma (superficial or deep) was recorded but diagnostic criteria had not 229 
been determined prospectively. Although in one study, bacterin therapy was less effective 230 
in dogs with deep pyoderma compared to those with superficial infections,24 unfortunately, 231 
this layer of analysis could not be included in this study. Furthermore, critical steps 232 
towards successful management of recurrent canine pyoderma remain the investigation 233 
and correction of primary diseases that lead to bacterial skin infection, most commonly 234 
ectoparasite infestations and allergic skin disease.7 31 Unfortunately, diagnostic 235 
investigations into such primary skin diseases seem rarely exhaustive in small animal 236 
practice as highlighted by a recent observational study that found that definitive diagnoses 237 
were only rarely reached before management decisions were made.32 Similarly, the results 238 
from our study indicate that ectoparasite prophylaxis, topical antimicrobial therapy and 239 
anti-inflammatory medication for dogs with allergic skin disease were probably underused 240 
with only 50% of dogs receiving veterinary-prescribed ectoparasite control and only 50% of 241 
allergic dogs receiving anti-inflammatory medication for their allergic skin disease.  242 
In current clinical practice, a major challenge to the treatment of canine pyoderma is the 243 
increasing prevalence of multidrug-resistant, methicillin-resistant S. pseudintermedius 244 
(MRSP).10 Autogenous bacterins may be of value in reducing selection pressure on 245 
opportunistic staphylococci by reducing the need for repeated systemic antimicrobial 246 
therapy and thus the risk of selection for MRSP. However, bacterin therapy has not been 247 
shown to speed up resolution of clinical signs, which should be the primary focus in the 248 
management of any MRSP infection in order to reduce the risk of contagion and zoonotic 249 
transmission. Furthermore, it remains unknown whether individual resistance genes are 250 
destroyed during bacterin production. Until this has been resolved, bacterins should only 251 
be prepared from methicillin-susceptible S. pseudintermedius to avoid the potential 252 
dispersal of resistance genes.  253 
In summary, the results from this study corroborate findings from the six earlier studies on 254 
canine recurrent pyoderma19-24 and expand the conclusions of a recent review that 255 
staphylococcal bacterin therapy can be of value in the management of canine recurrent 256 
pyoderma.33 Further investigations to better understand underlying mechanisms and 257 
optimise treatment are clearly needed. Such efforts would now be timely and relevant due 258 
to the high level of morbidity associated with canine recurrent pyoderma and the public 259 
health implications of repeated use of systemic antimicrobials that are classified as 260 
critically important for human health by the World Health Organisation.34  261 
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Table captions 357 
Table 1: Protocol and treatment recommendations provided to veterinary surgeons with 358 
each RVC Staphylococcus autogenous bacterin vial for injecting dogs. 359 
Table 2: Characteristics and antimicrobial therapy in the 12 months before and after 360 
starting autogenous Staphylococcus (pseud)intermedius bacterin for bacterial skin 361 
infections in 22 dogs. 362 
 363 
Table 1: Protocol and treatment recommendations provided to veterinary surgeons with 364 
each RVC Staphylococcus autogenous bacterin vial for injecting dogs 365 
Recommendations Treatment protocol 
Before starting induction 
bacterin therapy and during 
initial ten-day period 
Antibiotics should be withdrawn approximately 10 days 
after the injections begin, assuming that pyoderma is 
controlled. Once opened, please keep the bacterin 
refrigerated and inject subcutaneously every 3-4 days as 
follows: 
Day 1 1 ml 
Day 4 1 ml 
Day 8 2 ml 
Day 11 2 ml 
Day 15 3 ml 
Day 18 3 ml 
Subsequent induction 
therapy and maintenance  
Continue with 3 ml dose on a weekly basis.  
Continuation therapy If after three months the animal is responding favourably, 
then the injection interval can be extended to ten days 
and gradually to two weeks. 
 366 
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Table 2: Case characteristics and antimicrobial therapy before and after starting autogenous Staphylococcus 367 
(pseud)intermedius bacterin for bacterial skin infections in 22 dogs  368 
Dog 
number 
Breed Sex Body 
weight 
(kg) 
Age 
(years) 
Type of pyoderma as recorded in 
medical records 
Number of 
repeat 
orders  
Systemic antimicrobial therapy 
Courses 
before  
Courses 
after 
Days before Days after 
1 Unknown Not 
known 
28 Not 
known 
Deep interdigital 4 4 2 37 7 
2 Dalmatian F 30 6.5 Superficial and interdigital 3 11 7 81 77 
3 Cairn terrier M 13 7 Deep interdigital 3 3 4 27 77 
4 Shar Pei M 20 1.5 Superficial pyoderma 4 4 0 32 0 
5 Italian 
Spinone 
F 30 5.5 Superficial pyoderma 1 1 0 14 0 
6 Doberman M 39 2.2 Superficial and deep 11 6 2 96 27 
7 Bullterrier F 24 4.5 Deep pyoderma 12 6 5 237 65 
8 German 
shepherd 
F 29 5.4 Superficial pyoderma 4 3 8 76 77 
9 Yorkshire 
terrier 
F 4.5 11 Superficial pyoderma 2 9 6 190 196 
10 Yorkshire 
terrier 
F 4 10 Superficial pyoderma 3 6 2 116 27 
11 Cavalier 
King Charles 
spaniel 
M 12.5 8 Superficial pyoderma 1 3 6 59 46 
12 Labrador 
retriever 
M 35 6 Superficial pyoderma 1 6 3 43 65 
13 Labrador 
retriever 
M 32 6 Superficial pyoderma 1 6 5 65 133 
14 Rhodesian 
Ridgeback 
F 52 2 Superficial pyoderma 4 6 1 71 60  
15 Unknown M 43 Not 
known 
Superficial pyoderma 2 4 3 90 28 
16 Unknown F 32 2.5 Superficial pyoderma 0 4 0 60 0 
17 Labrador 
retriever 
M 29 8 Superficial pyoderma 9 4 0 47 0 
18 Crossbred M 19 9 Superficial pyoderma 8 7 7 138 99 
13 
 
19 Dogue de 
Bordeaux 
M 58 2 Superficial pyoderma 8 6 3 252 79 
20 Boxer F 24 4 Superficial pyoderma 0 1 1 15 5 
21 Irish Setter M 27 5 Deep pyoderma 3 3 0 98 0 
22 Crossbred F 37 4.5 Bacterial paronychia 0 7 3 228 203 
Summary 14 different 
breeds 
11 F, 11 
M 
Range 
4-58 
(median 
29)  
Range 
1.5-11 
(median 
5.4)  
68.2% superficial pyoderma, 9.1% 
superficial and deep, 18.2% deep 
pododermatitis, 1 bacterial 
paronychia 
Range 1-12 
(median 3)  
Range 1-11 
(median 5)  
Range 0-8 
(median 3) 
Range 14-252 
(median 74) 
Range 0-203 
(median 53) 
M: male; F: female.  369 
